Nonmyeloablative transplantation in children: Current status and future prospects

Hematology/Oncology Clinics of North America

Volumn 15, Issue 5, 2001, Pages 809-834

  Pulsipher, Michael A ^a   Woolfrey, Ann ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IDARUBICIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; SARCOLYSIN; THYMOCYTE ANTIBODY; VINCRISTINE;

ALLOTRANSPLANTATION; BLOOD DISEASE; CHILD CARE; CHIMERA; GENE THERAPY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HEMOGLOBINOPATHY; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; LYMPHOMA; MORBIDITY; MYELOID LEUKEMIA; ORGAN TRANSPLANTATION; PEDIATRIC SURGERY; PRIORITY JOURNAL; REVIEW; SAFETY; SOLID TUMOR; STEM CELL TRANSPLANTATION; STORAGE DISEASE; SURGICAL TECHNIQUE; TREATMENT INDICATION; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 0035676610     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70253-7     Document Type: Article

References (78)

1. Nonmyeloablative approaches to the treatment of sickle hemoglobinopathies
2. Nonmyeloblative stem cell transplantation for congenital immunodeficiencies
3. Non-myeloablative stem cell transplantation in adults with high-risk ALL
4. Chimerism studies after allogeneic non-myeloablative stem cell transplantation
5. Pure red cell aplasia (PRCA) and delayed erythroid engraftment in non-myeloablative (NM) PBSC transplantation with major ABO incompatibility
6. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma
7. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency
8. Non-myeloablative allogeneic hematopoietic cell transplantation (AHCT) for patients with myelodysplastic syndromes (MDS) and myeloproliferative disorders (MPD)
9. Allografting with immunosuppressive conditioning of low-dose fludarabine-cyclophosphamide after autografting
10. Autologous transplants followed by miniallografts for Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL)
11. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias
12. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
13. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses
14. Older patient age remains a risk factor for transplant related mortality (TRM) following nonmyeloablative allogeneic stem cell transplantation (NST)
15. Non-myeloablative allogeneic stem cell transplantation as immunotherapy for metastatic melanoma: Results of a pilot study
16. Engraftment syndrome following non-myeloablative conditioning therapy and HLA-matched bone marrow transplantation (BMT) for hematologic malignancy (HM)
17. Allografting for high-risk hematological and solid tumors: Reduced intensity chemotherapy followed by reinfusion of lymphocytes engineered with thymidine kinase gene
18. Allografting for patients with advanced hematological malignancies: Non-myeloablative conditioning followed by the reinfusion of lymphocytes engineered with HSV thymidine kinase gene
19. Unrelated donor bone marrow transplantation for correction of lethal congenital immunodeficiencies
20. Immunoablative (non-myeloablative) allogeneic SCT results in rapid full donor engraftment and early anti-tumor effects independent of DLI or GVHD prophylaxis withdrawal
21. Nonmyeloablative transplantation allows for enhanced T cell repertoire reconstitution in recipients of matched unrelated donor grafts compared to recipients of conventional myeloablative approaches
22. Minor-histocompatibility antigen (miHA)specific cytotoxic T-lymphocytes (CTL) generated with dendritic cells (DC) between dog leukocyte antigen (DLA)-identical littermates
23. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
24. Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
25. Allogeneic blood stem cell transplantation after dose reduced conditioning for patients with advanced solid tumors
26. Non-myeloablative allogeneic haematopoietic stem cell transplantation (HSCT) in two patients with colonic adenocarcinoma
27. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft
28. Expression of the SART1 tumor-rejection antigen in human osteosarcomas
29. Incidence of herpes virus infections following nonmyeloablative allogeneic stem cell transplantation
30. Fludarabine-based protocol for haploidentical peripheral blood stem cell transplantation in Hurler syndrome
31. Comparable survival for nonablative and ablative allogeneic transplantation for chronic lymphocytic leukemia (CLL): The case for early intervention
32. Transplant-Lite: Induction of graft-versus malignancy using fludarabine-based nonablabive chemotherapy chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
33. Umbilical cord blood transplantation in severe T-cell immunodeficiency disorders: Two-year experience
34. Adoptive immunotherapy in canine chimeras
35. In vivo CAMPATH-1H prevents graftversus-host disease following nonmyeloablative stem cell transplantation
36. Successful use of non-myeloablative therapy in the treatment of severe hemoglobinopathies: Proof of principle
37. Favorable outcome of non-myeloablative stem cell transplant (NMSCT) for chronic myeloid leukaemia (CML) in first chronic phase: A retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)
38. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
39. Marrow transplantation in thalassemia
40. Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy
41. Novel non-irradiation based preparative regimen for patients with Fanconi anemia (FA) and HLA-identical related hematopoietic cell donors
42. Human neuroblastoma cell lines are susceptible to lysis by NK cells but not be cytotoxic T lymphocytes
43. Comparisons of donor chimerism, graft rejection, and GVHD after hematopoietic stem cell transplants (HSCT) from HLA matched siblings and unrelated donors using conditioning with 2 Gy TBI with and without fludarabine (FLU)
44. Severe isolated CNS acceleration of ChediakHigashi syndrome treated by chemotherapy and non-myeloablative BMT
45. Successful stem cell transplantation following orthotopic liver transplantation from the same haploidentical family donor in a girl with hemophagocytic lymphohistiocytosis
46. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects
47. Bone marrow transplantation for hemoglobinopathies
48. Epstein-Barr virus-associated B cell lymphoproliferative disease after non-myeloablative allogeneic stem cell transplantation
49. HAL-A2402-restricted and tumor-specific cytotoxic T lymphocytes for tumor-infiltrating lymphocytes of a child with Wilm's tumor
50. Donor lymphocytes infusion postnon-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease
51. Allogeneic peripheral blood stem cell transplantation using a fudarabine-based low intensity conditioning regime for malignant lymphoma
52. The use of HLA-non-identical T-cell-depleted marrow transplants for correction of severe combined immunodeficiency disease
53. Allogeneic stem cell transplantation (SCT) in MDS: Interim results of outcome following non-myeloablative conditioning compared to standard preparative regimens
54. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children
55. Non-myeloablative stem cell transplant (NMSCT) in AML, ALL, and MDS: Disappointing outcome for patients with advanced phase disease
56. Higher than expected transplantrelated mortality and relapse following non-myeloablative stem cell transplantation for lymphoma adversely effects progression free survival
57. Allogeneic haematopoietic transplantation for Richter's syndrome
58. Mixed chimerism as an approach to transplantation tolerance
59. Nonmyeloablative transplants: Preclinical and clinical results
60. Induction of molecular remissions in chronic myelogenous leukemia (CML) with non-myeloablative HLA-identical sibling allografts
61. Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide specific cytotoxic T-lymphocytes
62. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors
63. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
64. Non-myeloablative allogeneic stem cell transplantation for the treatment of patients with chronic myeloid leukemia
65. T cell depleted haploidentical bone marrow transplantation for the treatment of children with severe combined immunodeficiency
66. Characterization of antigen-presenting properties of tumor virus specific cytotoxic T lymphocytes
67. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: The induction of allograft tolerance through mixed lymphohematopoietic chimerism
68. Haploidentical donor bone marrow transplantation (BMT) for advanced hematologic malignancy (HM) following non-myeloablative preparative therapy: Role of in vivo T-cell depletion with anti-thymocyte globulin or anti-CD2 monoclonal antibody therapy (MEDI-507)
69. Chronic graft-versus-host disease and other late complications of bone marrow transplantation
70. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms
71. Mixed lymphohaemopoietic chimerism and graftversus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bonemarrow transplantation
72. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer
73. Adjuvant treatment of canine osteosarcoma with the human cytotoxic T-cell line TALL-104
74. Collaborative multicenter investigation of marrow transplantation for sickle cell disease: Current results and future directions
75. Impact of bone marrow transplantation for symptomatic sickle cell disease: An interim report
76. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation
77. A nonmyeloablative regimen for induction of multi-lineage hematopoietic mixed donor-host chimerism in nonmalignant disorders
78. Hematopoietic cell transplantation for storage diseases